Patent · US Expired

1-[N2-((S)-ethoxycarbonyl)-3-phenylproply)-N6-trifluoroacetyl]-L-ysyl-L-proline (lisinopril (TFA) ethyl ester, LPE)

US6455705B1 · kind B1 · utility

0Cited by

7References

2Claims

0Family size

Assignee

Degussa AG · DE

Inventors

Matthias Kottenhahn · Alzenau, DE
Roland Moller · Herbrechtingen, DE
Michael Kraft · Blaustein, DE
Karlheinz Drauz · Alzenau, DE
Klaus Stingl · Alzenau, DE

Key dates

Filing date	Dec 24, 1998
Grant date	Sep 24, 2002
Priority date	—
Expiry date	Dec 24, 2018

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K38/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A method of isolating 1-[N2-((S)-ethoxycarbonyl)-3-phenylpropyl)-N6-trifluoroacetyl]-L-lysyl-L-proline (lisinopril (TFA) ethyl ester, LPE). The solvent or solvent mixture used for the extraction is also a main constituent of the solvent or solvent mixture from which the crystallization takes place. High yield as well as good purity of the end product are obtained, without distillation. 1-[N2-((S)-ethoxycarbonyl)-3-phenylpropyl)-N6-trifluoroacetyl]-L-lysyl-L-proline (lisinopril (TFA) ethyl ester, LPE) is described as a precursor for producing an ACE inhibitor.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.